Abstract

BackgroundHospital antimicrobial stewardship programs are critical in countries such as the Philippines, where antibiotic-resistant infections are highly prevalent. At our institution, a Prior Antimicrobial Restriction Approval (PARA) is required for noninfectious disease specialists to prescribe carbapenems. PARA request forms include specification of empiric or definitive therapy based on diagnostic tests. Recommended duration of therapy is typically 3 days for empiric use and 7 days for definitive, with possible extension upon specialist approval.MethodsThe study took place at an 800-bed tertiary hospital in Manila, Philippines. Using retrospective chart review, patients with a PARA request for carbapenems between January and December 2016 were identified. Information on patient demographics, hospital stay, infection, treatment, and outcomes was collected using the hospital’s online record system. Carbapenem use was scored as concordant or discordant based on guidelines of the Infectious Diseases Society of America: de-escalation based on culture data, length of carbapenem therapy, and/or consultation with an Infectious Disease Specialist.ResultsOf 183 patients on carbapenem therapy, 56 (31%) were classified as definitive and 127 (69%) were empiric (Table 1). In addition, 56 (44%) of the patients on empiric therapy were found to be guideline-discordant. The primary reason for discordance was failure to de-escalate the carbapenem following culture results (80% of cases with empiric prescriptions).Table 1:Characteristics of patient cases with requests for carbapenem therapyCases with PARA requestsTotal n = 183Definitive, n = 56Empiric, n = 127 P-valueAge (median, years)75.578.472.70.09Gender (% male)44.853.640.90.11Duration of carbapenem therapy (days)6.57.05.00.13Mortality (% deceased)23.017.925.20.28Recurrent infection (%)7.653.579.450.17Guideline-based carbapenem therapy (% concordant)59.069.654.30.05ConclusionPatients who were prescribed carbapenems empirically were more likely to have overall discordant therapy, which was often due to unnecessarily long antibiotic courses or failure to revise treatment based on laboratory data. Interventions that focus on drug de-escalation and incorporation of laboratory data into prescription choice should be implemented.Disclosures All authors: No reported disclosures.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call